About Us
Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.
Mission
Our Global Mission
To establish gene therapy as a new standard of care for the leading causes of vision loss.
Core Values
We are doing what’s never been done before driven by a higher purpose to go beyond – to develop and deliver functional cures for debilitating ocular diseases. We take pride in the work we do, and we take heart in the way we do it.
Lead with Integrity
We take individual and collective responsibility to put patients first and to make evidence-based decisions as we embark on a bold mission.
Pioneer with Patients
We use our science, technology, and expertise to innovate and optimize breakthrough products that preserve the sight of patients across the globe.
Strive Together
We aim high, tackling complex issues through diversity of perspectives, shared decision-making, and collaboration.
Sustainability
At Adverum, our values define how we conduct business, shape patient care, apply science to medicine, and work and grow as a company. We strive to put our corporate values into action every day – by reducing the environmental impact of our research and operations, providing safe, engaging and impactful work for our employees, and always leading with integrity.
To learn more, click here.
Sustainability Oversight
We integrate environmental, social, and governance objectives into our decision-making to deliver long-term value to all of our stakeholders. Our leadership creates and monitors our sustainability-related programs, with our board of directors maintaining ultimate oversight.
To identify the sustainability issues material to our business, we are guided by best practices, feedback we receive from our stakeholders, including employees, regulators, patients and investors, and third-party thought leaders, such as the Sustainability Accounting Standards Board (SASB), Biotechnology and Pharmaceuticals.
Leadership Team
Industry Leaders & Pioneers
Meet our team of industry-leaders, with deep experience in pioneering gene therapies and advancing innovative ophthalmology treatments, who are seeking to change the treatment paradigm for patients suffering from debilitating ocular diseases around the world.
Our Board of Directors has four standing committees: an Audit Committee, a Compensation Committee, a Nominating & Corporate Governance Committee and a Research & Development Committee.
The following table provides membership information for each committee.
| Name | Audit Committee | Compensation Committee | Nominating & Corporate Governance Committee | Research & Development Committee |
|---|---|---|---|---|
| Laurent |
||||
| Soo Hong | ||||
| Szilárd Kiss, M.D. | ||||
| Mark Lupher, Ph.D. | ||||
| Patrick Machado | ||||
| C. David |
||||
| James Scopa | ||||
| Dawn Svoronos | ||||
| Reed Tuckson, M.D. | ||||
| Scott Whitcup, M.D. |
Audit Committee
Patrick Machado
James Scopa
Dawn Svoronos
Compensation Committee
Soo Hong
Patrick Machado
James Scopa
Reed Tuckson, M.D.
Nominating & Corporate Governance Committee
Mark Lupher, Ph.D.
Dawn Svoronos
Reed Tuckson, M.D.
Scott Whitcup, M.D.
Research & Development Committee
Szilárd Kiss, M.D.
Mark Lupher, Ph.D.
C. David
Scott Whitcup, M.D.
Chairperson of the Board
Committee Chairperson
Committee Member
Working at Adverum
Join our team of visionaries and disruptors to see beyond each breakthrough and help patients live their lives fully – in vision, action, and expression.
